Yu Xu, Wu Hao, Zhou Lei, Wang Gaoxiang, Sun Xinyi, Miao Junjun, Ben Meijie, Shi Rongwei, Wan Shimei, Li Shasha, Wang Xiaoci, Zhou Xiqiao, Zhao Yue
Department of Endocrinology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Department of Ophthalmology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Front Endocrinol (Lausanne). 2025 May 2;16:1556310. doi: 10.3389/fendo.2025.1556310. eCollection 2025.
This study aimed to evaluate the role of hyperoside in ameliorating the retinal injury of diabetic retinopathy (DR) rats and the dysfunction of retinal endothelial cells (RECs) in high glucose.
RECs were cultured in various groups including high glucose and different concentrations of hyperoside. The viability, migration, and tube formation of RECs and the expression of transforming growth factor-beta 1 (TGF-β1)/micro-RNA 200b (miR-200b)/vascular endothelial growth factor (VEGF) in each group were assayed. Sprague-Dawley rats were used for DR modeling and were treated with hyperoside. The tissue pathology of the rat retina and the expression of TGF-β1/miR-200b/VEGF in the retinal tissues of each group were examined.
Excessive proliferation, migration, and tube formation of RECs were induced by high glucose. The retinal pathological changes and vasculopathy in DR rats were more serious compared with those in normal rats. The expression levels of TGF-β1 and VEGF in the high glucose-induced REC group and in DR rat retina were markedly upregulated, but those of miR-200b were noticeably downregulated. However, hyperoside could significantly inhibit the high glucose-induced overproliferation, migration, and tube formation of RECs, alleviate the retinal injury in DR rats, and reverse the expression of TGF-β1/miR-200b/VEGF in the high glucose-induced REC and DR rat retina, dose-dependently.
Hyperoside could ameliorate retinal injury in DR rats and the high glucose-induced dysfunction of RECs by regulating the TGF-β1/miR-200b/VEGF pathway.
本研究旨在评估金丝桃苷在改善糖尿病视网膜病变(DR)大鼠视网膜损伤及高糖环境下视网膜内皮细胞(RECs)功能障碍中的作用。
将RECs培养于不同组,包括高糖组及不同浓度金丝桃苷组。检测各组RECs的活力、迁移能力、成管能力以及转化生长因子-β1(TGF-β1)/微小RNA 200b(miR-200b)/血管内皮生长因子(VEGF)的表达。采用Sprague-Dawley大鼠建立DR模型并给予金丝桃苷治疗。检查大鼠视网膜的组织病理学以及各组视网膜组织中TGF-β1/miR-200b/VEGF的表达。
高糖诱导RECs过度增殖、迁移及成管。与正常大鼠相比,DR大鼠的视网膜病理改变和血管病变更严重。高糖诱导的RECs组及DR大鼠视网膜中TGF-β1和VEGF的表达水平显著上调,但miR-200b的表达水平明显下调。然而,金丝桃苷可显著抑制高糖诱导的RECs过度增殖、迁移及成管,减轻DR大鼠的视网膜损伤,并剂量依赖性地逆转高糖诱导的RECs组及DR大鼠视网膜中TGF-β1/miR-200b/VEGF的表达。
金丝桃苷可通过调节TGF-β1/miR-200b/VEGF通路改善DR大鼠的视网膜损伤及高糖诱导的RECs功能障碍。